Literature DB >> 28401528

Association between low C-peptide and fragility fractures in postmenopausal women without diabetes.

Y Ferro1, C Russo1, D Russo2, C Gazzaruso3, A Coppola3, P Gallotti3, V Zambianchi3, M Fodaro3, S Romeo1,4, E Galliera5, M G Marazzi6, M M C Romanelli6, S Giannini7,8, A Pujia1, T Montalcini9.   

Abstract

PURPOSE: C-peptide has been shown to exert several, previously unknown, biological effects. A recent cross-sectional study demonstrated an association between low C-peptide serum levels and low lumbar bone density of postmenopausal women not affected by diabetes. To date, very little research attention has been directed toward the association between C-peptide and osteoporotic fractures. To contribute toward filling this gap, we investigated the association between C-peptide and fractures in postmenopausal women.
METHODS: A cohort of 133 non-diabetic postmenopausal women with and without a history of fractures was evaluated in this cross-sectional investigation. Standardized interviews were performed to gather information on the patients' fracture history. All of the participants underwent a bone mineral density assessment by DXA, radiographs, and a serum C-peptide measurement.
RESULTS: Thirty-four women presented fractures. Bivariate analysis revealed an inverse correlation between C-peptide and fractures (r = -0.27, p = 0.002). A significant difference in mean C-peptide levels was also found between women with vs. without fractures (p = 0.01, adjusted for age, BMI and glucose). Logistic regression analysis showed that C-peptide levels, femoral and vertebral BMD were all negatively associated with fracture status (B = -1.097, ES = 0.401, p = 0.006, 95% CI 0.15-0.73; B = -15.6, SE = 4.17, p < 0.001, CI 0.001-0.002; B = -24.8, SE = 5.23, p < 0.001, CI 0001-0.002; respectively).
CONCLUSIONS: This study confirms an inverse association between serum C-peptide levels and a history of fractures in postmenopausal women without diabetes. These results suggest that C-peptidemay exert an effect on bone mineral density. However, further large-scale studies are needed to corroborate this finding and investigate the potential underlying mechanisms involved.

Entities:  

Keywords:  C-Peptide; Diabetes; Fractures; Osteoporosis; Postmenopausal women

Mesh:

Substances:

Year:  2017        PMID: 28401528     DOI: 10.1007/s40618-017-0672-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

1.  Risk factors for ankle fracture.

Authors:  D M Greenfield; R Eastell
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

Review 2.  Alcohol and bone: review of dose effects and mechanisms.

Authors:  D B Maurel; N Boisseau; C L Benhamou; C Jaffre
Journal:  Osteoporos Int       Date:  2011-09-17       Impact factor: 4.507

Review 3.  Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice.

Authors:  V V Zhukouskaya; C Eller-Vainicher; A P Shepelkevich; Y Dydyshko; E Cairoli; I Chiodini
Journal:  J Endocrinol Invest       Date:  2015-04-12       Impact factor: 4.256

4.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

5.  Alcohol consumption and hip fractures: the Framingham Study.

Authors:  D T Felson; D P Kiel; J J Anderson; W B Kannel
Journal:  Am J Epidemiol       Date:  1988-11       Impact factor: 4.897

6.  Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers.

Authors:  M T Saha; H Sievänen; M K Salo; S Tulokas; H H Saha
Journal:  Osteoporos Int       Date:  2008-12-13       Impact factor: 4.507

7.  Determinants of bone mineral density in older men.

Authors:  N W Glynn; E N Meilahn; M Charron; S J Anderson; L H Kuller; J A Cauley
Journal:  J Bone Miner Res       Date:  1995-11       Impact factor: 6.741

Review 8.  The clinical potential of C-peptide replacement in type 1 diabetes.

Authors:  John Wahren; Asa Kallas; Anders A F Sima
Journal:  Diabetes       Date:  2012-04       Impact factor: 9.461

9.  C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation.

Authors:  Mahendra Prasad Bhatt; Young-Cheol Lim; JongYun Hwang; SungHun Na; Young-Myeong Kim; Kwon-Soo Ha
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

10.  Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.

Authors:  John M Lachin; Paula McGee; Jerry P Palmer
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.